KR20020063064A - 리도카인의 1회 용량이 연질캅셀에 충진되어 있는단위투여형제제 - Google Patents
리도카인의 1회 용량이 연질캅셀에 충진되어 있는단위투여형제제 Download PDFInfo
- Publication number
- KR20020063064A KR20020063064A KR1020010003796A KR20010003796A KR20020063064A KR 20020063064 A KR20020063064 A KR 20020063064A KR 1020010003796 A KR1020010003796 A KR 1020010003796A KR 20010003796 A KR20010003796 A KR 20010003796A KR 20020063064 A KR20020063064 A KR 20020063064A
- Authority
- KR
- South Korea
- Prior art keywords
- lidocaine
- soft capsule
- capsule
- soft
- unit dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 229960004194 lidocaine Drugs 0.000 title claims abstract description 32
- 239000007901 soft capsule Substances 0.000 title claims abstract description 30
- 239000002904 solvent Substances 0.000 claims abstract description 9
- 239000002552 dosage form Substances 0.000 claims abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 5
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 12
- 238000009472 formulation Methods 0.000 claims description 5
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 230000003444 anaesthetic effect Effects 0.000 abstract description 4
- 230000003381 solubilizing effect Effects 0.000 abstract description 3
- 230000003631 expected effect Effects 0.000 abstract description 2
- 206010036596 premature ejaculation Diseases 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 229920003080 Povidone K 25 Polymers 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940100487 povidone k25 Drugs 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 2
- PPWHTZKZQNXVAE-UHFFFAOYSA-N Tetracaine hydrochloride Chemical compound Cl.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 PPWHTZKZQNXVAE-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 229960001309 procaine hydrochloride Drugs 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960002494 tetracaine hydrochloride Drugs 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 108010025899 gelatin film Proteins 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
| 경과기간 | 시험기준 | 초기 | 2개월 | 4개월 | 6개월 |
| 성상 | 미황색 젤라틴 피막에든 무색투명한 외용액제 | 적합 | 적합 | 적합 | 적합 |
| 확인시험 | 침전반응 | 적합 | 적합 | 적합 | 적합 |
| 중량편차 | 표시양 이상 및 90%이하인 것이 1개 이하 | 적합 | 적합 | 적합 | 적합 |
| 미생물오염시험 | 10만개, 100개/g 및 음성 | 적합 | 적합 | 적합 | 적합 |
Claims (3)
- 국소마취제로서 리도카인 1회 용량이 연질캅셀에 충진되어 있는 단위투여형 제제.
- 제 1항에 있어서, 리도카인의 가용화제로 폴리에칠렌글리콜류의 비휘발성 용제를 사용하는 것을 특징으로 하는 단위투여형 제제.
- 제 2항에 있어서, 폴리에칠렌글리콜류가 폴리에칠렌글리콜 400인 것을 특징으로 하는 단위투여형 제제.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020010003796A KR20020063064A (ko) | 2001-01-26 | 2001-01-26 | 리도카인의 1회 용량이 연질캅셀에 충진되어 있는단위투여형제제 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020010003796A KR20020063064A (ko) | 2001-01-26 | 2001-01-26 | 리도카인의 1회 용량이 연질캅셀에 충진되어 있는단위투여형제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20020063064A true KR20020063064A (ko) | 2002-08-01 |
Family
ID=27692495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020010003796A Ceased KR20020063064A (ko) | 2001-01-26 | 2001-01-26 | 리도카인의 1회 용량이 연질캅셀에 충진되어 있는단위투여형제제 |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20020063064A (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507561B2 (en) | 2009-01-22 | 2013-08-13 | Absorption Pharmaceuticals, LLC | Desensitizing drug product |
-
2001
- 2001-01-26 KR KR1020010003796A patent/KR20020063064A/ko not_active Ceased
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8507561B2 (en) | 2009-01-22 | 2013-08-13 | Absorption Pharmaceuticals, LLC | Desensitizing drug product |
| US8563616B2 (en) | 2009-01-22 | 2013-10-22 | Absorption Pharmaceuticals, LLC | Desensitizing drug product |
| US8637577B2 (en) | 2009-01-22 | 2014-01-28 | Absorption Pharmaceuticals, LLC | Desensitizing drug product |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4472376A (en) | Pharmaceutical insertion compositions and a process for producing the same | |
| FI78235B (fi) | Foerfarande foer framstaellning av en topisk anti-inflammatorisk komposition i gelsalvaform. | |
| ES2201487T3 (es) | Liberacion controlada de farmacos administrados por via sublingual o bucal. | |
| JP5319691B2 (ja) | プラジカンテル、マクロライドラクトン、シクロデキストリンおよび粘稠化剤を含む駆虫ペースト | |
| BG100763A (bg) | Орални течни фармацевтични състави,съдържащи пароксетин резинат | |
| JP2000505093A (ja) | 苦味薬剤の味の良い水性液体組成物 | |
| KR910005885B1 (ko) | 염화리소짐 및 글리치르히진산 디칼륨 함유 수용액제제 | |
| HUP0105173A2 (hu) | Adagolási módszer és készítmény sürgősségi fogamzásgátlásra | |
| BR112015008459B1 (pt) | uso de dexmedetomidina, medetomidina ou um sal farmaceuticamente aceitável destas para a fabricação de um medicamento para aliviar a aversão ao ruído em um animal | |
| US11147810B2 (en) | Pharmaceutical composition of oral suspension of anti-neoplastic alkylating agents | |
| US6103257A (en) | System for delivering pharmaceuticals to the buccal mucosa | |
| Sarojini et al. | Oral medicated jellies–a review | |
| KR20020063064A (ko) | 리도카인의 1회 용량이 연질캅셀에 충진되어 있는단위투여형제제 | |
| CN116056704A (zh) | 吡喹酮制剂 | |
| CN101983052B (zh) | 一种通过跨口腔粘膜途径进行曲坦类药物给药的药物制剂 | |
| KR100344198B1 (ko) | 실데나필 시트레이트의 속효제형 | |
| JP2001072576A (ja) | 経口用医薬品組成物 | |
| Anitha et al. | Pharmaceutical Oral Jellies-An Overview | |
| AU2015101787A4 (en) | Antiparasitic formulations for oral administration | |
| BR112020024399A2 (pt) | composição líquida sem água e sistema para administração transmucosal oral de um ingrediente ativo através de uma composição líquida | |
| AU2007221747B2 (en) | Medicament | |
| PL247528B1 (pl) | Płynna kompozycja inhibitorów fosfodiesterazy typu 5 (PDE-5), sposób jej wytwarzania oraz jej zastosowanie do leczenia zaburzeń erekcji | |
| CA3210430A1 (en) | Solid orodispersible pharmaceutical composition in film containing lorazepam | |
| Alisherovna et al. | SELECTION OF BASES FOR SUPPOSITORIES OF COGLUMET IMMUNOMODULATORY ACTION | |
| WO2001082915A2 (en) | Trans-clitoral administration of therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20010126 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20051229 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20010126 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20061121 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20070222 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20061121 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |